Pharmaceutical company MSD once again has to prepare for a waiting period prior to knowing whether the Danish Medicines Council will approve its big seller, cancer remedy Keytruda (pembrolizumab) targeting a particular type of lung cancer.
Quite unexpectedly, the council elected during its latest meeting on Wednesday to put the remedy, which would benefit at least 300 patients a year, on temporary hold, so-called extended clock-stop.
Get full access for you and your coworkers.Start a free company trial today
Already a member? Log in.